The security and efficacy of erlotinib have not been proven for patients with NSCLC whose tumors clearly show other EGFR mutations. On top of that it is not advisable for use in combination with platinum-primarily based chemotherapy. Label Erlotinib or gefitinib coupled with chemotherapy as first-line therapy for individuals with https://fccp57902.daneblogger.com/26983247/pemigatinib-an-overview